Company / SG&A Expense
KalVista Pharmaceuticals, Inc. SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$116.3M
FY2024
5-year range
$26.4M / $116.3M
FY2020-FY2024
Trend
+114.2%
vs FY2023
Sector context
#105 of 213
Health Care
What the data says
At $116M, KalVista Pharmaceuticals, Inc.'s sg&a expense ranks #109 of 213 in the Health Care sector. SG&A Expense has increased for 6 consecutive years, from $3M in FY2018 to $116M in FY2024.
Based on SEC 10-K filings.
$116M in FY2024 with a 5-year CAGR of +59.7%.
Increased from $31M to $116M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +63.8%
- 5-Year CAGR
- +59.7%
- 10-Year CAGR
- -
Sector benchmark
#109 of 213 in Health CareTop 51% of 213This company $116.3M Sector average $722.3M
▼
-83.9% below sector average
Key checks
Key Insights
- KalVista Pharmaceuticals, Inc.'s sg&a expense has grown for 6 consecutive years.
- 5-year CAGR of +59.7%, indicating consistent growth.
- In FY2024, sg&a expense increased 114.2% year-over-year.
- Ranks #105 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.72 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $116.3M | +114.2% |
| FY2023 | $54.3M | +77.4% |
| FY2022 | $30.6M | +15.7% |
| FY2021 | $26.4M | +59.0% |
| FY2020 | $16.6M | +48.9% |
| FY2019 | $11.2M | +321.3% |
| FY2018 | $2.7M | -70.1% |
| FY2017 | $8.9M | -20.7% |
| FY2016 | $11.2M | +595.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026